Ketoacidosis as unexpected adverse reaction SGLT<sub>2</sub> inhibitor

Ketoacidosis as unexpected adverse reaction SGLT<sub>2</sub> inhibitor

Inhibitors of the sodium-glucose cotransporter-2 SGLT2 is a new class of hypoglycemic drugs. This article presents the information on FDA reports (2013-2015) and AIS (May 2015 - February 2016) on the risk of new adverse reaction - ketoacidosis. Conjectural pathophysiological mechanisms of ADR associ...

Full description

Bibliographic Details
Main Authors: T. M. Bukatina, A. S. Kazakov, N. Yu. Velts, M. A. Darmostukova, K. E. Zatolochina, R. N. Alyautdin, V. P. Dobrynin, B. K. Romanov
Format: Article
Language:Russian
Published: Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation  2018-02-01
Series:Безопасность и риск фармакотерапии
Subjects:
ингибиторы sglt<sub>2</sub>
кетоацидоз
сахарный диабет 2 типа
дапаглифлозин
inhibitors of sglt2
ketoacidosis
type 2 diabetes
dapagliflozin
Online Access:https://www.risksafety.ru/jour/article/view/58

Internet

https://www.risksafety.ru/jour/article/view/58

Similar Items